QUARTERLY UPDATE | News for Donors, Sponsors, Patients, Doctors, and Hospitals • The Jed Ian Taxel Foundation for Rare Cancer Research 


WE CAN DEFEAT RARE CANCER
WE CAN SAVE LIVES   

Greetings!

Barely two short years ago, we launched The Jed Ian Taxel Foundation for Rare Cancer Research to fund innovative rare cancer research and to accelerate discovery of groundbreaking treatments that can save lives.

We’ve accomplished so much together. In this short time – and thanks to YOU – the “JEDI” community has contributed over $440,000 dollars to rare cancer research initiatives, with significantly more to come in 2023. 
GET THE FACTS ON
RARE CANCER

  • One in four cancers diagnosed annually is a rare cancer.

  • Over 200,000 patients in the U.S. are diagnosed with a rare cancer each year and these patients have little hope of a positive outcome.

  • Every pediatric cancer is considered rare and affects one in 285 children globally.

  • Cancer experts generally agree that funding is primarily focused on the prevalent “common” cancers and fails to sufficiently fund rare cancer research.
NEW SCIENCE OFFERS
NEW HOPE 

  • You are helping scientists answer some of the toughest questions about rare cancers, including how they develop and spread, and why some are resistant to treatment.

  • You are equipping researchers with the state-of-the-art technology they need to analyze tumor samples faster and more accurately than ever before.

  • You are making it possible for doctors to run innovative clinical trials and deliver new therapies to people with rare cancers in real time.
Thank you for bringing new hope to people around the world.
 
With gratitude and respect,
Mark Taxel
Chairman and CEO
Harmony Knutson 
President

ON THE HORIZON:
2024 RARE CANCER MOONSHOT WORKSHOP
The Jed Ian Taxel Foundation for Rare Cancer Research in partnership with Case Comprehensive Cancer Center and additional stakeholders are developing a “Rare Cancer Moonshot Workshop” with the goal to DEFINE SYSTEMIC RESOURCES AND NATIONAL POLICY NEEDS TO ACCELERATE THE DEFEAT OF RARE CANCERS.
 
THE NEED: Treatments for “common cancers,” which make up 75% of all cancers, have made considerable progress in patient survival rates over the past 25 years (from 50% to 70% overall 5-year survival); patients with a rare cancer, which comprises 25% of all cancers diagnosed annually in the U.S., have not participated in that improvement. 
 
THE HOPE: New transformative science, particularly single-cell molecular analytics, genetic sequencing, and immunotherapies have made possible new approaches to develop new pathways for treatments and cures. The goal of the workshop is to build a consensus on how to build a coordinated effort that accelerates progress … a roadmap that delineates resource needs, collaborative models, industry opportunities, and government policy improvements.
Thank you once again for coming together in support of Cycle for Survival 2023.
 
We had an amazing turnout and thanks to your unwavering support, we raised more than $100,000 in support of rare cancer research at Memorial Sloan Kettering. We are humbled by the incredible community who continue to help make a difference. 
 
Together, we can create positive change in the world and
work towards finding new treatments and cures. 
The Jed Ian Taxel Foundation for Rare Cancer Research, Inc. is a 501(c)(3) Nonprofit Organization, accepting Tax Deductible Donations from individuals, corporations, family-advised funds, and foundations. Federal Tax ID 86-261081